Genetic Function – Page 2

Talzenna, Xtandi, metastatic castration-resistant prostate cancer (mCRPC), overall survival, TALAPRO-2 trial, PARP inhibitor, homologous recombination repair (HRR) gene mutations

Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

4 months ago talkbio0Tagged AML, Breakthrough Therapy, DNA Sequence Rearrangement, Identifier, KMT2A gene, KOMET-001, KOMET-017, Leukemia, Myelocytic, Acute, Menin Inhibitor, Mutation, NPM1, NPM1 gene, Phase 3 trials, Ziftomenib

Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation

J&J’s Subcutaneous Rybrevant Receives CHMP Backing for Lung Cancer Treatment Despite Recent FDA Rejection

4 months ago talkbio0Tagged amivantamab, CHMP, Epidermal Growth Factor Receptor, Johnson & Johnson, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous formulation, United States Food and Drug Administration

Rybrevant, amivantamab, Johnson & Johnson, CHMP, FDA, subcutaneous formulation, non-small cell lung cancer, EGFR mutations

J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

4 months ago talkbio0Tagged chemotherapy-free regimen, Epidermal Growth Factor Receptor, Lazcluze, Mutation, Non-Small Cell Lung Carcinoma, Overall Survival, Phase III MARIPOSA trial, Rybrevant, Tagrisso

Rybrevant, Lazcluze, Tagrisso, NSCLC, EGFR mutation, overall survival, Phase III MARIPOSA trial, chemotherapy-free regimen

Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy

5 months ago talkbio0Tagged Age related macular degeneration, Bausch, Cities, Geographic Atrophy, Lomb, Ophthalmologic diseases, RNA Interference, strategic collaboration

Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases